Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.24 AUD | 0.00% | 0.00% | +2.13% |
Feb. 28 | Transcript : Capitol Health Limited, H1 2024 Earnings Call, Feb 29, 2024 | |
Feb. 28 | Capitol Health Posts 20% Rise in H1 FY24 Revenue, Returns to Profit | MT |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company benefits from high valuations in earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.13% | 169M | C | ||
-18.58% | 8.3B | B+ | ||
+47.25% | 3.78B | C+ | ||
-8.58% | 2.47B | - | ||
-38.71% | 2.46B | B- | ||
-10.06% | 2.31B | B- | ||
-5.44% | 1.95B | C- | ||
-17.79% | 1.59B | A- | ||
-40.78% | 1.21B | C+ | ||
+6.69% | 1.1B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CAJ Stock
- Ratings Capitol Health Limited